Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”).
The AGM will be held at 10.30 a.m. on 21 November 2023 at the Company’s new registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.
Shareholders will shortly be sent either printed copies of the Notice of AGM and accompanying materials or a letter notifying them that they are available on the Company’s website, depending on the preferences they have expressed to the Company’s registrar.
A copy of the Notice of AGM, containing further details of the resolutions, as well as a copy of the Company’s Annual Report and Accounts will be made available today on the Company’s website at www.physiomics.co.uk/investors/reports-prospectus/.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.